Back
#1
14.3%
Top 2%
10.7%
Top 11%
8.8%
Top 2%
7.6%
Top 78%
5.8%
Top 7%
5.4%
Top 3%
4.9%
Top 68%
3.8%
Top 0.6%
3.8%
Top 1%
2.7%
Top 3%
1.9%
Top 3%
1.9%
Top 3%
1.9%
Top 6%
1.9%
Top 0.4%
1.5%
#1
1.5%
Top 2%
1.5%
Top 4%
1.5%
Top 3%
1.3%
Top 24%
0.9%
Top 6%
0.7%
Top 8%
0.7%
Top 4%
0.7%
Top 11%
0.7%
Belantamab Mafodotin Triggers Immune Invigoration in Multiple Myeloma Via Inflammatory and Immunogenic Cell Death
2025-09-12
oncology
Title + abstract only
View on medRxiv
Show abstract
Belantamab mafodotin, an antibody-drug conjugate targeting B-cell maturation antigen, has demonstrated significant clinical efficacy in combination therapies for relapsed/refractory multiple myeloma. Belantamab mafodotin exerts therapeutic effects through cytotoxicity of its payload, monomethyl auristatin F, and through mediation of antibody-induced cell death. Long-term clinical responses were observed with monotherapy treatment, despite dose holds, suggesting adaptive immune system involvement...
Predicted journal destinations
1
Clinical Cancer Research
22 training papers
2
Cancers
57 training papers
3
Nature Communications
483 training papers
4
Frontiers in Oncology
34 training papers
5
PLOS ONE
1737 training papers
6
eLife
262 training papers
7
Frontiers in Immunology
140 training papers
8
Scientific Reports
701 training papers
9
Blood Advances
16 training papers
10
Journal of Clinical Investigation
50 training papers
11
Cancer Medicine
17 training papers
12
British Journal of Cancer
22 training papers
13
iScience
74 training papers
14
Proceedings of the National Academy of Sciences
100 training papers
15
Cell Reports
25 training papers
16
EMBO Molecular Medicine
15 training papers
17
International Journal of Molecular Sciences
39 training papers
18
BMC Cancer
21 training papers
19
Cell Reports Medicine
49 training papers
20
JAMA Network Open
125 training papers
21
Communications Biology
36 training papers
22
Communications Medicine
63 training papers
23
Science Translational Medicine
40 training papers
24
Nature
58 training papers